Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
Oxford Biomedica, which has an 18-month supply deal with AstraZeneca to make its AZD1222 vaccine, lifted forecasts for expected cumulative revenues to more than £100m by end-2021 from more than £50m.
As a result, Oxford Biomedica said it expected ‘significant growth’ in annual operating earnings for the year to end-December.
